JANSSEN PRODS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PRODS, and what generic alternatives to JANSSEN PRODS drugs are available?
JANSSEN PRODS has eight approved drugs.
There are twenty-three US patents protecting JANSSEN PRODS drugs.
There are seven hundred and eighty-seven patent family members on JANSSEN PRODS drugs in sixty-four countries and two hundred and forty-eight supplementary protection certificates in nineteen countries.
Summary for JANSSEN PRODS
| International Patents: | 787 |
| US Patents: | 23 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 8 |
Drugs and US Patents for JANSSEN PRODS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | YONDELIS | trabectedin | POWDER;INTRAVENOUS | 207953-001 | Oct 23, 2015 | RX | Yes | Yes | 8,895,557*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 7,671,032 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | 7,390,791 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 8,148,399 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 9,623,022 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 8,754,106 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Janssen Prods | PREZCOBIX | cobicistat; darunavir | TABLET;ORAL | 205395-001 | Jan 29, 2015 | RX | Yes | Yes | 8,518,987*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN PRODS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 8,597,876 | ⤷ Sign Up |
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 6,703,396 | ⤷ Sign Up |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-006 | Nov 9, 2012 | 6,335,460*PED | ⤷ Sign Up |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-002 | Feb 25, 2008 | RE43596*PED | ⤷ Sign Up |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-006 | Nov 9, 2012 | 8,597,876*PED | ⤷ Sign Up |
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | 8,518,987 | ⤷ Sign Up |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-004 | Dec 18, 2008 | RE42889*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
International Patents for JANSSEN PRODS Drugs
Supplementary Protection Certificates for JANSSEN PRODS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2487166 | 2016/061 | Ireland | ⤷ Sign Up | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119 |
| 2049506 | C20150046 00250 | Estonia | ⤷ Sign Up | PRODUCT NAME: KOBITSISTAAT;REG NO/DATE: EU/1/13/830/001-002 27.05.2013 |
| 3808743 | CR 2022 00035 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER RILPIVIRINHYDROCHLORID, OG EMTRICITABIN; REG. NO/DATE: EU/1/11/737/001-002 20111128 |
| 1419152 | 132012902054377 | Italy | ⤷ Sign Up | PRODUCT NAME: EMTRICITABINA/RILPIVIRINA CLORIDRATO/TENOFOVIR DISOPROXIL FUMARATO(EVIPLERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/737/001-002, 20111128 |
| 3808743 | CA 2022 00035 | Denmark | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIC ACID SALT OF RILPIVIRINE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737/001-002 20111128 |
| 3808743 | PA2022515 | Lithuania | ⤷ Sign Up | PRODUCT NAME: RILPIVIRINO ARBA TERAPINIU POZIURIU EKVIVALENTISKOS JO FORMOS APSAUGOTOS PAGRINDINIU PATENTU, TOKIOS KAIP FARMACINIU POZIURIU PRIIMTINOS PRIDETINES RILPIVIRINO DRUSKOS, ISKAITANT RILPIVIRINO HIDROCHLORIDO RUGSTIES DRUSKA, IR EMTRICITABINO DERINYS; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 2487166 | 132017000002828 | Italy | ⤷ Sign Up | PRODUCT NAME: COBICISTAT O UN SALE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO E TENOFOVIR ALAFENAMIDE O UN SALE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO, IN PARTICOLARE TENOFOVIR ALAFENAMIDE FUMARATO(GENVOYA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1061, 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
